206 related articles for article (PubMed ID: 27639713)
1. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.
Nassiri N; Margolis DJ; Natarajan S; Sharma DS; Huang J; Dorey FJ; Marks LS
J Urol; 2017 Mar; 197(3 Pt 1):632-639. PubMed ID: 27639713
[TBL] [Abstract][Full Text] [Related]
2. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
3. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
4. Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
Chang E; Jones TA; Natarajan S; Sharma D; Simopoulos D; Margolis DJ; Huang J; Dorey FJ; Marks LS
J Urol; 2018 Jan; 199(1):98-105. PubMed ID: 28728993
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
Siddiqui MM; Rais-Bahrami S; Truong H; Stamatakis L; Vourganti S; Nix J; Hoang AN; Walton-Diaz A; Shuch B; Weintraub M; Kruecker J; Amalou H; Turkbey B; Merino MJ; Choyke PL; Wood BJ; Pinto PA
Eur Urol; 2013 Nov; 64(5):713-719. PubMed ID: 23787357
[TBL] [Abstract][Full Text] [Related]
6. Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
Lai WS; Gordetsky JB; Thomas JV; Nix JW; Rais-Bahrami S
Cancer; 2017 Jun; 123(11):1941-1948. PubMed ID: 28140460
[TBL] [Abstract][Full Text] [Related]
7. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
Tran GN; Leapman MS; Nguyen HG; Cowan JE; Shinohara K; Westphalen AC; Carroll PR
Eur Urol; 2017 Aug; 72(2):275-281. PubMed ID: 27595378
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
[TBL] [Abstract][Full Text] [Related]
9. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer.
Kinnaird A; Yerram NK; O'Connor L; Brisbane W; Sharma V; Chuang R; Jayadevan R; Ahdoot M; Daneshvar M; Priester A; Delfin M; Tran E; Barsa DE; Sisk A; Reiter RE; Felker E; Raman S; Kwan L; Choyke PL; Merino MJ; Wood BJ; Turkbey B; Pinto PA; Marks LS
J Urol; 2022 Apr; 207(4):823-831. PubMed ID: 34854746
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.
Kamrava M; Kishan AU; Margolis DJ; Huang J; Dorey F; Lieu P; Kupelian PA; Marks LS
Pract Radiat Oncol; 2015; 5(6):411-6. PubMed ID: 26059510
[TBL] [Abstract][Full Text] [Related]
12. Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.
Dieffenbacher S; Nyarangi-Dix J; Giganti F; Bonekamp D; Kesch C; Müller-Wolf MB; Schütz V; Gasch C; Hatiboglu G; Hauffe M; Stenzinger A; Duensing S; Schlemmer HP; Moore CM; Hohenfellner M; Radtke JP
Eur Urol Focus; 2021 Jan; 7(1):102-110. PubMed ID: 30878348
[TBL] [Abstract][Full Text] [Related]
13. Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
Bloom JB; Hale GR; Gold SA; Rayn KN; Smith C; Mehralivand S; Czarniecki M; Valera V; Wood BJ; Merino MJ; Choyke PL; Parnes HL; Turkbey B; Pinto PA
J Urol; 2019 Jan; 201(1):84-90. PubMed ID: 30577395
[TBL] [Abstract][Full Text] [Related]
14. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?
Hu JC; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Sonn G; Dorey FJ; Marks LS
J Urol; 2014 Aug; 192(2):385-90. PubMed ID: 24512956
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
[TBL] [Abstract][Full Text] [Related]
17. Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy.
Garcia-Reyes K; Nguyen HG; Zagoria RJ; Shinohara K; Carroll PR; Behr SC; Westphalen AC
J Urol; 2018 Mar; 199(3):699-705. PubMed ID: 28941918
[TBL] [Abstract][Full Text] [Related]
18. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
[TBL] [Abstract][Full Text] [Related]
19. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
Washington SL; Baskin AS; Ameli N; Nguyen HG; Westphalen AC; Shinohara K; Carroll PR
AJR Am J Roentgenol; 2020 Mar; 214(3):574-578. PubMed ID: 31913068
[No Abstract] [Full Text] [Related]
20. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.
Radtke JP; Kuru TH; Bonekamp D; Freitag MT; Wolf MB; Alt CD; Hatiboglu G; Boxler S; Pahernik S; Roth W; Roethke MC; Schlemmer HP; Hohenfellner M; Hadaschik BA
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):283-91. PubMed ID: 27184812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
